Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer.

Jensen LH, Olesen R, Petersen LN, Boysen AK, Andersen RF, Lindebjerg J, Nottelmann L, Thomsen CEB, Havelund BM, Jakobsen A, Hansen TF.

Cancers (Basel). 2019 Oct 25;11(11). pii: E1649. doi: 10.3390/cancers11111649.

2.

Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Secondary Analysis of a Randomized Trial.

Appelt AL, Andersen RF, Lindebjerg J, Jakobsen A.

Am J Clin Oncol. 2019 Sep 27. doi: 10.1097/COC.0000000000000609. [Epub ahead of print]

PMID:
31569168
3.

Nephrotic syndrome is associated with increased plasma K+ concentration, intestinal K+ losses and attenuated urinary K+ excretion - studies in rats and humans.

Ydegaard R, Svenningsen P, Bistrup C, Andersen RF, Stubbe J, Buhl KB, Marcussen N, Hinrichs GR, Iraqi H, Zamani R, Dimke H, Jensen BL.

Am J Physiol Renal Physiol. 2019 Sep 30. doi: 10.1152/ajprenal.00179.2019. [Epub ahead of print]

PMID:
31566427
4.

An evaluation of phase angle, bioelectrical impedance vector analysis and impedance ratio for the assessment of disease status in children with nephrotic syndrome.

Brantlov S, Jødal L, Andersen RF, Lange A, Rittig S, Ward LC.

BMC Nephrol. 2019 Aug 22;20(1):331. doi: 10.1186/s12882-019-1511-y.

5.

Quantification of microRNA in plasma using probe based TaqMan assays: is microRNA purification required?

Binderup HG, Madsen JS, Brasen CL, Houlind K, Andersen RF.

BMC Res Notes. 2019 May 10;12(1):261. doi: 10.1186/s13104-019-4301-5.

6.

Acute intravenous acyl ghrelin infusion induces thirst but does not affect sodium excretion: two randomized, double-blind, placebo-controlled crossover studies in hypopituitary patients.

Vestergaard ET, Møller N, Andersen RF, Rittig S, Jørgensen JOL.

Eur J Endocrinol. 2019 Jul 1;181(1):23-30. doi: 10.1530/EJE-19-0027.

PMID:
31075759
7.

Delta tocotrienol in recurrent ovarian cancer. A phase II trial.

Thomsen CB, Andersen RF, Steffensen KD, Adimi P, Jakobsen A.

Pharmacol Res. 2019 Mar;141:392-396. doi: 10.1016/j.phrs.2019.01.017. Epub 2019 Jan 9.

8.

Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment.

Thomsen CB, Andersen RF, Lindebjerg J, Hansen TF, Jensen LH, Jakobsen A.

Clin Colorectal Cancer. 2019 Mar;18(1):28-33.e3. doi: 10.1016/j.clcc.2018.10.004. Epub 2018 Oct 24.

PMID:
30459076
9.

Childhood onset steroid-sensitive nephrotic syndrome continues into adulthood.

Korsgaard T, Andersen RF, Joshi S, Hagstrøm S, Rittig S.

Pediatr Nephrol. 2019 Apr;34(4):641-648. doi: 10.1007/s00467-018-4119-8. Epub 2018 Nov 13.

PMID:
30426221
10.

Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses.

Andersen RF.

Expert Rev Mol Diagn. 2018 Dec;18(12):1011-1019. doi: 10.1080/14737159.2018.1545576. Epub 2018 Nov 13. Review.

PMID:
30411633
11.

Quantification of microRNA levels in plasma - Impact of preanalytical and analytical conditions.

Binderup HG, Madsen JS, Heegaard NHH, Houlind K, Andersen RF, Brasen CL.

PLoS One. 2018 Jul 19;13(7):e0201069. doi: 10.1371/journal.pone.0201069. eCollection 2018.

12.

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.

Thomsen CB, Hansen TF, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A.

J Exp Clin Cancer Res. 2018 Mar 12;37(1):55. doi: 10.1186/s13046-018-0723-5.

13.

Infants with prenatally diagnosed kidney anomalies have an increased risk of urinary tract infections.

Rasmussen M, Sunde L, Andersen RF, Petersen OB; Danish Fetal Medicine Research Group, Olsen MS.

Acta Paediatr. 2017 Nov;106(11):1875-1881. doi: 10.1111/apa.14014. Epub 2017 Sep 4.

PMID:
28793177
14.

Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Spindler KG, Boysen AK, Pallisgård N, Johansen JS, Tabernero J, Sørensen MM, Jensen BV, Hansen TF, Sefrioui D, Andersen RF, Brandslund I, Jakobsen A.

Oncologist. 2017 Sep;22(9):1049-1055. doi: 10.1634/theoncologist.2016-0178. Epub 2017 Aug 4. Review.

15.

Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy.

Eriksen AHM, Sørensen FB, Andersen RF, Jakobsen A, Hansen TF.

Oncol Lett. 2017 Jul;14(1):201-209. doi: 10.3892/ol.2017.6141. Epub 2017 May 9.

16.

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab.

Hansen TF, Andersen RF, Olsen DA, Sørensen FB, Jakobsen A.

Sci Rep. 2017 May 24;7(1):2388. doi: 10.1038/s41598-017-02538-x.

17.

The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer.

Thomsen CEB, Appelt AL, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A.

Cancer Med. 2017 May;6(5):928-936. doi: 10.1002/cam4.1051. Epub 2017 Apr 4.

18.

Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer.

Eriksen AH, Andersen RF, Nielsen BS, Sørensen FB, Appelt AL, Jakobsen A, Hansen TF.

PLoS One. 2016 Jun 3;11(6):e0156919. doi: 10.1371/journal.pone.0156919. eCollection 2016.

19.

Screening for circulating RAS/RAF mutations by multiplex digital PCR.

Andersen RF, Jakobsen A.

Clin Chim Acta. 2016 Jul 1;458:138-43. doi: 10.1016/j.cca.2016.05.007. Epub 2016 May 12.

PMID:
27181912
20.

MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer.

Eriksen AH, Andersen RF, Pallisgaard N, Sørensen FB, Jakobsen A, Hansen TF.

PLoS One. 2016 Mar 3;11(3):e0150593. doi: 10.1371/journal.pone.0150593. eCollection 2016.

21.

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.

Spindler KL, Pallisgaard N, Appelt AL, Andersen RF, Schou JV, Nielsen D, Pfeiffer P, Yilmaz M, Johansen JS, Hoegdall EV, Jakobsen A, Jensen BV.

Eur J Cancer. 2015 Nov;51(17):2678-85. doi: 10.1016/j.ejca.2015.06.118. Epub 2015 Oct 24.

PMID:
26508156
22.

Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene Amplification.

Sørensen PD, Andersen RF, Pallisgaard N, Madsen JS, Jakobsen EH, Brandslund I.

J Circ Biomark. 2015 Aug 31;4:9. doi: 10.5772/61320. eCollection 2015 Jan-Dec.

23.

Circulating microRNAs as biomarkers of adult Crohn's disease.

Jensen MD, Andersen RF, Christensen H, Nathan T, Kjeldsen J, Madsen JS.

Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1038-44. doi: 10.1097/MEG.0000000000000430.

PMID:
26230660
24.

Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.

Stæhr M, Buhl KB, Andersen RF, Svenningsen P, Nielsen F, Hinrichs GR, Bistrup C, Jensen BL.

Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F235-41. doi: 10.1152/ajprenal.00138.2015. Epub 2015 May 13.

25.

Controls to validate plasma samples for cell free DNA quantification.

Pallisgaard N, Spindler KL, Andersen RF, Brandslund I, Jakobsen A.

Clin Chim Acta. 2015 Jun 15;446:141-6. doi: 10.1016/j.cca.2015.04.015. Epub 2015 Apr 18.

PMID:
25896958
26.

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.

Spindler KL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A.

PLoS One. 2015 Apr 13;10(4):e0108247. doi: 10.1371/journal.pone.0108247. eCollection 2015.

27.

Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons.

Andersen RF, Spindler KL, Brandslund I, Jakobsen A, Pallisgaard N.

Clin Chim Acta. 2015 Jan 15;439:97-101. doi: 10.1016/j.cca.2014.10.011. Epub 2014 Oct 20.

PMID:
25446878
28.

Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab.

Steffensen KD, Madsen CV, Andersen RF, Waldstrøm M, Adimi P, Jakobsen A.

Eur J Cancer. 2014 Oct;50(15):2611-8. doi: 10.1016/j.ejca.2014.06.022. Epub 2014 Jul 30.

PMID:
25087181
29.

Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.

Spindler KL, Appelt AL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A.

Int J Cancer. 2014 Dec 15;135(12):2984-91. doi: 10.1002/ijc.28946. Epub 2014 Jun 17.

30.

Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.

Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Int J Cancer. 2014 Nov 1;135(9):2215-22. doi: 10.1002/ijc.28863. Epub 2014 Apr 17.

31.

Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'.

Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Br J Cancer. 2014 Dec 9;111(12):2380. doi: 10.1038/bjc.2014.115. Epub 2014 Mar 11. No abstract available.

32.

Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.

Spindler KL, Pallisgaard N, Andersen RF, Ploen J, Jakobsen A.

Anticancer Res. 2014 Feb;34(2):845-50.

PMID:
24511021
33.

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.

Dowler Nygaard A, Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Oncol Rep. 2014 Feb;31(2):969-74. doi: 10.3892/or.2013.2906. Epub 2013 Dec 6.

PMID:
24316734
34.

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.

Spindler KG, Appelt AL, Pallisgaard N, Andersen RF, Jakobsen A.

Br J Cancer. 2013 Dec 10;109(12):3067-72. doi: 10.1038/bjc.2013.633. Epub 2013 Nov 21.

35.

MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.

Hansen TF, Christensen Rd, Andersen RF, Sørensen FB, Johnsson A, Jakobsen A.

Br J Cancer. 2013 Sep 3;109(5):1243-51. doi: 10.1038/bjc.2013.448. Epub 2013 Aug 6.

36.

Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.

Spindler KL, Sorensen MM, Pallisgaard N, Andersen RF, Havelund BM, Ploen J, Lassen U, Jakobsen AK.

Acta Oncol. 2013 Jun;52(5):963-70. doi: 10.3109/0284186X.2013.776175. Epub 2013 Mar 20.

PMID:
23514584
37.

Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC.

Andersen RF, Buhl KB, Jensen BL, Svenningsen P, Friis UG, Jespersen B, Rittig S.

Pediatr Nephrol. 2013 Aug;28(8):1227-34. doi: 10.1007/s00467-013-2439-2. Epub 2013 Mar 16.

PMID:
23503750
38.

Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients.

Sørensen PD, Jakobsen EH, Madsen JS, Petersen EB, Andersen RF, Østergaard B, Brandslund I.

J Cancer Res Clin Oncol. 2013 Jun;139(6):1005-13. doi: 10.1007/s00432-013-1411-7. Epub 2013 Mar 13.

PMID:
23483255
39.

Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer.

Bechmann T, Andersen RF, Pallisgaard N, Madsen JS, Maae E, Jakobsen EH, Bak Jylling AM, Steffensen KD, Jakobsen A.

J Cancer Res Clin Oncol. 2013 Jun;139(6):995-1003. doi: 10.1007/s00432-013-1413-5. Epub 2013 Mar 12.

PMID:
23479212
40.

High plasma aldosterone is associated with a risk of reversible decreased eGFR in childhood idiopathic nephrotic syndrome.

Andersen RF, Nørgaard H, Hagstrøm S, Bjerre J, Jespersen B, Rittig S.

Nephrol Dial Transplant. 2013 Apr;28(4):944-52. doi: 10.1093/ndt/gfs527. Epub 2013 Jan 14.

PMID:
23322739
41.

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Lung Cancer. 2013 Mar;79(3):312-7. doi: 10.1016/j.lungcan.2012.11.016. Epub 2012 Dec 11.

PMID:
23238036
42.

Mechanisms of renal NaCl retention in proteinuric disease.

Svenningsen P, Friis UG, Versland JB, Buhl KB, Møller Frederiksen B, Andersen H, Zachar RM, Bistrup C, Skøtt O, Jørgensen JS, Andersen RF, Jensen BL.

Acta Physiol (Oxf). 2013 Mar;207(3):536-45. doi: 10.1111/apha.12047. Epub 2013 Jan 7. Review.

PMID:
23216619
43.

Single nucleotide polymorphisms in the HIF-1α gene and chemoradiotherapy of locally advanced rectal cancer.

Havelund BM, Spindler KL, Ploen J, Andersen RF, Jakobsen A.

Oncol Lett. 2012 Nov;4(5):1056-1060. Epub 2012 Jul 31.

44.

The influence of tissue ischemia on biomarker expression in colorectal cancer.

Havelund BM, Olsen DA, Andersen RF, Spindler KL, Brandslund I, Jakobsen A, Soerensen FB.

Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):298-307. doi: 10.1097/PAI.0b013e31826f4475.

PMID:
23060299
45.

Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.

Maae E, Andersen RF, Steffensen KD, Jakobsen EH, Brandslund I, Sørensen FB, Jakobsen A.

Anticancer Res. 2012 Sep;32(9):3619-27.

PMID:
22993299
46.

Plasma and urine proteomic profiles in childhood idiopathic nephrotic syndrome.

Andersen RF, Palmfeldt J, Jespersen B, Gregersen N, Rittig S.

Proteomics Clin Appl. 2012 Aug;6(7-8):382-93. doi: 10.1002/prca.201100081.

PMID:
22927352
47.

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.

Hansen TF, Christensen Rd, Andersen RF, Garm Spindler KL, Johnsson A, Jakobsen A.

Int J Colorectal Dis. 2012 Jun;27(6):715-20. doi: 10.1007/s00384-011-1382-6. Epub 2011 Dec 6.

PMID:
22139032
48.

Reduced anti-diuretic response to desmopressin during wet nights in patients with monosymptomatic nocturnal enuresis.

Tauris LH, Andersen RF, Kamperis K, Hagstroem S, Rittig S.

J Pediatr Urol. 2012 Jun;8(3):285-90. doi: 10.1016/j.jpurol.2011.03.018. Epub 2011 Apr 22.

PMID:
21514237
49.

Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome.

Andersen RF, Thrane N, Noergaard K, Rytter L, Jespersen B, Rittig S.

Pediatr Nephrol. 2010 Jul;25(7):1299-304. doi: 10.1007/s00467-010-1537-7. Epub 2010 May 6.

PMID:
20446093
50.

Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer.

Hansen TF, Sørensen FB, Spindler KL, Olsen DA, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A.

Virchows Arch. 2010 Mar;456(3):251-60. doi: 10.1007/s00428-009-0878-8. Epub 2010 Feb 9.

PMID:
20143086

Supplemental Content

Loading ...
Support Center